From February 2017, information about the work of the MRC/CSO Social and Public Health Sciences Unit, University of Glasgow is available and updated on the University of Glasgow website.

Unit Image

This is an archived page.

Content is not current and concerns research previously undertaken by the Unit.

Staff Member Biography

Elisabeth Fenwick

position: Senior Lecturer in Health Economics

Contact Details

email:
phone: 0141 330 4039

Address

MRC/CSO Social and Public Health Sciences Unit,
University of Glasgow,
Top floor,
200, Renfield Street
Glasgow
G2 3QB

Biography and Interests

Elisabeth Fenwick joined the unit in 2006 as a joint appoitment with Health Policy at the University of Glasgow. A health economist, her role is to provide economic evaluation input into a variety of projects within the unit. Liz has an M.Sc. and PhD in Health Economics from the University of York and an M.Sc. in Operations Research from the University of Southampton. During 2002/03 she spent a year as a visiting Postdoctoral Fellow at the Centre for Evaluation of Medicines (CEM), at McMaster University, Canada.

Her research interests centre around the application of decision analytic modelling to economic evaluation, probabilistic decision analytic modelling, Bayesian decision theory and value of information analysis. Her thesis presented an iterative framework for the efficient management of the HTA process incorporating probabilistic decision analytic modelling, value of information analysis and Bayesian updating. Her current research includes expanding this framework to incorporate and assess the value of implementation strategies.

Click for further information on Dr Elisabeth Fenwick

Publications

2010

Briggs A H, Ritchie K, Fenwick E, Chalkidou K, Littlejohns P. Access with evidence development in the UK: past experiences, current initiatives and future potential. PharmacoEconomics 2010;28:163-70

Lawson KD, Fenwick E, Pell ACH, Pell JP. Comparison of mass and targeted screening strategies for cardiovascular risk: simulation of the effectiveness, cost-effectiveness and coverage from a cross sectional survey of 3,291 people. Heart 2010;96:208-12

Lorgelly P, Lawson K, Fenwick E, Briggs A. Outcome measurement in economic evaluations of public health interventions: a role for the capability approach?. International Journal of Environmental Research and Public Health 2010;7:2274-89

Walker S, Mason A, Claxton K, Cookson R, Fenwick E, Fleetcroft R, Sculpher M. Value for money and the quality and outcomes framework in primary care in the UK NHS. British Journal of General Practice 2010;60:e213-20

2009

Hoomans T, Fenwick E, Palmer S, Claxton K. Value of information and value of implementation: application of an analytical framework to inform resource allocation decisions in Metastatic Hormone-Refractory Prostate Cancer . Value in Health 2009;12:315-24

pubmed  

2008

Barton G, Briggs A, Fenwick E. Optimal cost-effectiveness decisions: the role of the Cost-Effectiveness Acceptability Curve (CEAC), the Cost-Effectiveness Acceptability Frontier (CEAF), and the Expected Value of Perfection Information (EVPI). Value in Health 2008;11:886-897

pubmed  open access  

Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Medical Decision Making 2008;28:21-32

pubmed  

Fenwick E, Marshall DA, Blackhouse G, Vidaillet H, Slee A, Shemanski L, Levy AR. Assessing the impact of censoring of costs and effects on health-care decision-making: an example using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Value in Health 2008;11:365-75

pubmed  

Fitzsimons C, Baker G, Wright A, Nimmo M, Ward-Thompson C, Lowry R, Millington C, Shaw R, Fenwick E, Ogilvie D, Inchley J, Foster C, Mutrie N. The ‘Walking for Wellbeing in the West’ randomised controlled trial of a pedometer-based walking programme in combination with a physical activity consultation with 12 month follow-up: rationale and study design. BMC Public Health 2008;8:259

pubmed  open access  

2007

Asseberg C, Bravo Y, Palmer S, Fenwick E, de Belder M, Abrams K, Sculpher M. Assessing the effectiveness of primary angioplasty compared to thrombolysis and its relationship to time delay: a Bayesian evidence synthesis. Heart 2007;93:1244-50

pubmed  

Bravo Vergel Y, Palmer S, Asseburg C, Fenwick E, de Belder M, Abrams K, Sculpher M. Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis. Heart 2007;93:1238-1243

pubmed  

Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer A, Riemsma R. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technology Assessment 2007;11:iii-iv, xv-xviii, 1-179

pubmed  open access  

Fenwick E, Briggs A. Cost–effectiveness acceptability curves in the dock: case not proven?. Medical Decision Making 2007;27:93-95

pubmed  

2006

Claxton K, Fenwick E, Sculpher M. Decision-making with uncertainty: the value of information. In: Jones AM, editor Elgar companion to health economics. Cheltenham: Elgar Publishing, 2006:514-525.

Collins R, Trowman R, Norman G, Light K, Birtle A, Fenwick E, Palmer S, Riemsma R. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. British Journal of Cancer 2006;95:457-462

Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Services Research 2006;6:52

pubmed  

Fenwick E, Palmer S, Claxton K, Sculpher M, Abrams K, Sutton A. An iterative Bayesian approach to health technology assessment: application to a policy of pre-operative optimisation for patients undergoing major elective surgery. Medical Decision Making 2006;26:480-496

2005

Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. British Journal of Psychiatry 2005;187:106-108

pubmed  

Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. CHE Research Paper series no. 5, 2005

O'Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, Fenwick E, Fryback D, Sculpher M, Spiegelhalter D, Willan A. Incorporation of uncertainty in health economic modelling studies. PharmacoEconomics 2005;23:529-536

pubmed  

Severens JL, Brunenberg DEM, Fenwick E, O'Brien B, Joore MA. Cost-effectiveness acceptability curves and a reluctance to lose. PharmacoEconomics 2005;23:1207-1214

pubmed  

2004

Claxton K., Fenwick E, Palmer S, Sculpher M, Abrams K, Sutton A. Building a reference case for Bayesian applications to health economics and outcomes research: report to the Bayesian Initiative. 2004

Fenwick E, O'Brien B, Briggs A.. Cost-effectiveness acceptability curves: facts, fallacies and FAQ. Health Economics 2004;13:405-415

Marshall D, Levy AR, Vidaillet H, Fenwick E, Slee A, Blackhouse G, Greene HL, Wyse DG, Nichol G, O'Brien BJ, AFFIRM Investigators , CORE Investigators. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Annals of Internal Medicine 2004;141:653-661

open access  

2002

Fenwick E, Claxton K, Sculpher M, Wilson RJ. Pre-operative optimisation employing dopexamine or adrenaline for patients undergoing major elective surgery: a cost-effectiveness analysis. Intensive Care Medicine 2002;28:599-608

2001

Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics 2001;10:779-787